No­var­tis wants to be a leader in a new gen­er­a­tion of pre­scrip­tion dig­i­tal med pro­grams, pairs with Pear

The new­ly emerg­ing field of pre­scrip­tion dig­i­tal med­i­cine is tak­ing a big step for­ward to­day.

Phar­ma gi­ant No­var­tis $NVS is pair­ing up with Pear Ther­a­peu­tics, one of the lead­ing pi­o­neers in the are­na, to de­vel­op new mo­bile apps for pa­tients with schiz­o­phre­nia and mul­ti­ple scle­ro­sis.

You may re­call that Pear broke new ground a few months ago by gain­ing an FDA ap­proval for an app de­signed to help pa­tients with sub­stance abuse dis­or­der. Now the Boston/Bay Area-based biotech will work with Joris van Dam, the ex­ec­u­tive di­rec­tor for dig­i­tal ther­a­peu­tics at the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, on in­ter­ac­tive dig­i­tal pro­grams for schiz­o­phre­nia and mul­ti­ple scle­ro­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER